Código QR (código de barras bidimensional)

An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: An overview of previous and ongoing studies with perspectives on the future

Ropeginterferon alfa-2b is a novel, long-acting mono-pegylated proline-IFN-alpha-2b approved for treatment of polycythemia vera in adults, regardless of thrombotic risk level or treatment history. Clinical trial data indicate the dose and titration of ropeginterferon alfa-2b is safe and effective. H...

ver descrição completa

Na minha lista:
Principais autores: Albert Qin, Raymond W. Urbanski, Lennex Yu, Tasfia Ahmed, John Mascarenhas
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2023-01-01
coleção:Frontiers in Oncology
Assuntos:
ropeginterferon alfa-2b
myeloproliferative neoplasm
polycythemia vera
alternative dosing strategy
clinical study
interferon
Acesso em linha:https://www.frontiersin.org/articles/10.3389/fonc.2023.1109866/full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados